---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-018552"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2023-05-17T23:59:59+00:00"
generated_at: "2026-06-14T22:41:07.536291+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine presents preclinical data on CGD correction and PASSIGE CAR-T platform at ASGCT

## Summary
- Prime editing corrected CGD mutation in >90% of CD34+ cells from four donors with no off-target edits detected.
- Long-term engraftment >92% editing in vivo supports PM359 advancement as CGD treatment candidate.
- PASSIGE platform inserted CD19 CAR (3.5 kb) at TRAC locus in 60% of T cells, with >90% TCR loss.
- PASSIGE-generated CAR-T cells showed potent anti-tumor activity in vitro and in vivo.
- Multiplex prime editing achieved >90% B2M knockout in primary T cells, enabling allogeneic CAR-T potential.

## SEC filing metadata
- accession: 0001628280-23-018552
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2023-05-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828023018552/0001628280-23-018552-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828023018552/prme-20230517.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-018552
- JSON: https://secwatch.observer/filing/0001628280-23-018552.json
- Plain text: https://secwatch.observer/filing/0001628280-23-018552.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.